DECEMBER 2022 | ALERT NO. 071

ForwardHealth ALERT

Wisconsin serving you

TO

All Providers, HMOs and Other Managed Care Programs

REGARDING

Bebtelovimab Monoclonal Antibody Therapy Not Currently Authorized for Commercial Distribution

Bebtelovimab Monoclonal Antibody Therapy Not Currently Authorized for Commercial Distribution

On November 30, 2022, the U.S. Food and Drug Administration (FDA) announced that bebtelovimab monoclonal antibody therapy is not currently authorized for the administration for COVID-19 treatment in the United States. The Division of Medicaid Services will continue to follow the guidance and recommendations of the FDA, the Centers for Disease Control and Prevention, and the Centers for Medicare & Medicaid Services.

Eli Lilly, the manufacturer of bebtelovimab monoclonal antibody therapy, has placed a pause on bebtelovimab for commercial distribution until further notice. Providers are encouraged to retain all bebtelovimab supply in the event that any coronavirus variants that are susceptible to bebtelovimab become more prevalent.

Claims Submitted to ForwardHealth for the Administration of Bebtelovimab

ForwardHealth will continue to accept claims submitted for dates of service before November 30, 2022, with the following Healthcare Common Procedure Coding System procedure codes:

- Q0222 (Injection, bebtelovimab, 175 mg)
- M0222 (Intravenous injection, bebtelovimab, includes injection and post administration monitoring)
- M0223 (Intravenous injection, bebtelovimab, includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that hasbeen made provider-based to the hospital during the COVID-19 public health emergency)

More Information About COVID-19

COVID-19-related ForwardHealth Alerts and Updates are available on the COVID-19: ForwardHealth News and Resources page of the ForwardHealth Portal.